Central venous catheter care for the patient with cancer: American Society of Clinical Oncology clinical practice guideline CA Schiffer, PB Mangu, JC Wade, D Camp-Sorrell, DG Cope, ... J Clin Oncol 31 (10), 1357-1370, 2013 | 460 | 2013 |
Targeting the epidermal growth factor receptor BF El-Rayes, PM LoRusso British journal of cancer 91 (3), 418-424, 2004 | 231 | 2004 |
Intensity-modulated radiotherapy (IMRT) and concurrent capecitabine for pancreatic cancer E Ben-Josef, AF Shields, U Vaishampayan, V Vaitkevicius, BF El-Rayes, ... International Journal of Radiation Oncology* Biology* Physics 59 (2), 454-459, 2004 | 228 | 2004 |
Apoptosis-inducing effect of chemotherapeutic agents is potentiated by soy isoflavone genistein, a natural inhibitor of NF-κB in BxPC-3 pancreatic cancer cell line Y Li, KL Ellis, S Ali, BF El-Rayes, A Nedeljkovic-Kurepa, O Kucuk, ... Pancreas 28 (4), e90-e95, 2004 | 172 | 2004 |
Potentiation of the effect of erlotinib by genistein in pancreatic cancer: the role of Akt and nuclear factor-κB BF El-Rayes, S Ali, IF Ali, PA Philip, J Abbruzzese, FH Sarkar Cancer research 66 (21), 10553-10559, 2006 | 162 | 2006 |
Yttrium-90 radioembolization for unresectable standard-chemorefractory intrahepatic cholangiocarcinoma: survival, efficacy, and safety study S Rafi, SM Piduru, B El-Rayes, JS Kauh, DA Kooby, JM Sarmiento, ... Cardiovascular and interventional radiology 36, 440-448, 2013 | 149 | 2013 |
mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by … HJ Prajapati, JR Spivey, SI Hanish, BF El-Rayes, JS Kauh, Z Chen, ... Annals of oncology 24 (4), 965-973, 2013 | 146 | 2013 |
Exploitation of protein kinase C: a useful target for cancer therapy AS Ali, S Ali, BF El-Rayes, PA Philip, FH Sarkar Cancer treatment reviews 35 (1), 1-8, 2009 | 139 | 2009 |
Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locallyadvanced prostate cancer M Hussain, DC Smith, BF El-Rayes, W Du, U Vaishampayan, J Fontana, ... Urology 61 (4), 774-780, 2003 | 137 | 2003 |
Pronecrotic mixed lineage kinase domain‐like protein expression is a prognostic biomarker in patients with early‐stage resected pancreatic adenocarcinoma LE Colbert, SB Fisher, CW Hardy, WA Hall, B Saka, JW Shelton, ... Cancer 119 (17), 3148-3155, 2013 | 127 | 2013 |
Carbohydrate antigen 19‐9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine‐containing chemotherapy: a pooled … TM Bauer, BF El‐Rayes, X Li, N Hammad, PA Philip, AF Shields, ... Cancer 119 (2), 285-292, 2013 | 127 | 2013 |
A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers BF El-Rayes, M Zalupski, T Bekai-Saab, LK Heilbrun, N Hammad, B Patel, ... Annals of oncology 21 (10), 1999-2004, 2010 | 127 | 2010 |
Antiangiogenic effects of ganetespib in colorectal cancer mediated through inhibition of HIF-1α and STAT-3 PN Ganji, W Park, J Wen, H Mahaseth, J Landry, AB Farris, F Willingham, ... Angiogenesis 16, 903-917, 2013 | 116 | 2013 |
A phase II study of celecoxib, gemcitabine, and cisplatin in advanced pancreatic cancer BF El-Rayes, MM Zalupski, AF Shields, AM Ferris, U Vaishampayan, ... Investigational new drugs 23, 583-590, 2005 | 111 | 2005 |
Cyclooxygenase-2-dependent and-independent effects of celecoxib in pancreatic cancer cell lines BF El-Rayes, S Ali, FH Sarkar, PA Philip Molecular cancer therapeutics 3 (11), 1421-1426, 2004 | 110 | 2004 |
The impact of curcumin on breast cancer GP Nagaraju, S Aliya, SF Zafar, R Basha, R Diaz, BF El-Rayes Integrative Biology 4 (9), 996-1007, 2012 | 107 | 2012 |
Pleiotropic effects of genistein in metabolic, inflammatory, and malignant diseases GP Nagaraju, SF Zafar, BF El-Rayes Nutrition reviews 71 (8), 562-572, 2013 | 102 | 2013 |
Cytochrome p450 and glutathione transferase expression in human breast cancer BF El-Rayes, S Ali, LK Heilbrun, S Lababidi, D Bouwman, D Visscher, ... Clinical Cancer Research 9 (5), 1705-1709, 2003 | 100 | 2003 |
Apoptosis-inducing effect of erlotinib is potentiated by 3,3′-diindolylmethane in vitro and in vivo using an orthotopic model of pancreatic cancer S Ali, S Banerjee, A Ahmad, BF El-Rayes, PA Philip, FH Sarkar Molecular cancer therapeutics 7 (6), 1708-1719, 2008 | 98 | 2008 |
Novel synthetic curcumin analogues EF31 and UBS109 are potent DNA hypomethylating agents in pancreatic cancer GP Nagaraju, S Zhu, J Wen, AB Farris, VN Adsay, R Diaz, JP Snyder, ... Cancer letters 341 (2), 195-203, 2013 | 93 | 2013 |